University of Pittsburgh

University of Michigan

Georgia Tech Research Corporation

Carnegie Mellon University

Joel Steven Schuman

Hiroshi Ishikawa

Alan H Wells

Cecelia C Yates-Binder

Gadi Wollstein

Steven R Little

Kira Lynn Lathrop

Lawrence Edward Kagemann

Morgan V Fedorchak

Chaim-Gadi Wollstein

James Rehg

James L Funderburgh

Chieh-Li Chen

Ian P Conner

Jong S Kim

Yu-Ying Liu

Juan Xu

Anthony Cugini

David Tolliver

Yiqin Du

Sayoko Eileen Moroi

Chaim Gad Wollstein

Weixang Dai

Nirmala SundarRaj

Mei Chen

Lawrence E Kagemann, Jr

Morgan V DiLeo

A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days.

Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery

Methods for treating an ear condition in a subject, comprising topically administering to the ear of the subject in need thereof a composition comprising: (i) an anti-infective agent-loaded biodegradable polymer microspheres; and (ii) a thermoresponsive hydrogel.

Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery

The innovation provides for a system and method available to image and visualize the palisades of Vogt via a non-contact process, analyze the image volumes acquired, evaluate the status of the palisades of Vogt from the data represented therein, and display the data in real-time or as a part of a medical record for ongoing.

Optical Coherence Tomography as a rapid, accurate, non-contact method of visualizing the palisades of Vogt

Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear

The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-&#x3b3;-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal &#x3b1;-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.

Activators of CXCR3 for the treatment of angiopathies of the eye

The present invention is directed to systems and methods for generating virtually averaged optical coherence tomography (Oct.) images. An illustrative method can include receiving an image, identifying a first voxel of the image, and selecting a plurality of local voxels of the image. Each of the plurality of local voxels is within a defined region of the first voxel. The values of the plurality of local voxels can indicate an appearance of the local voxels in the image.

Image enhancement using virtual averaging

A method for determining a disease state transition path includes receiving a patient data having functional data and/or structural data related to a patient. Based on the patient data, a first disease state of a plurality of non-overlapping disease states each associated with a predetermined range of functional and/or structural degeneration values may be identified. A second, non-adjacent disease state of the plurality of disease states may be identified based on the patient data. A most probable path between the first disease state and the second disease state may be determined using a two dimensional continuous-time hidden Markov model.

Systems and methods for disease progression modeling

The innovation provides for a system and method available to image and visualize the palisades of Vogt via a non-contact process, analyze the image volumes acquired, evaluate the status of the palisades of Vogt from the data represented therein, and display the data in real-time or as a part of a medical record for ongoing consideration and evaluation.

Optical coherence tomography as a rapid, accurate, non-contact method of visualizing the palisades of Vogt

The present disclosure describes systems and method for generating surgical maps that provide a surgeon with information regarding the placement of features of interest. More particularly, the system is configured to display optical coherence tomography (OCT) images to a medical professional. The medical professional can select anatomical features, biomarkers, and other features of interest within each of the OCT images. The system can then translate the location of the features of interest within the OCT images to an en face image to generate a map of the features that the medical professional can use for surgical guidance.

Mapping of internal features on en face imagery

Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.

Goblet cell replacement therapy

Provided herein are isolated populations of multipotent stem cells capable of differentiating into trabecular meshwork (TM) cells, methods of obtaining an isolated population of TM cells, and isolated populations of TM cells obtained therefrom. Compositions, kits, and devices comprising the isolated populations of multipotent stem cells or TM cells are also provided herein. Further provided are methods of using the compositions, kits, and devices for decreasing intraocular pressure in an eye, increasing cell density in a trabecular meshwork of an eye, increasing outflow of aqueous humor from an eye, or treating or preventing a medical condition in a subject.

Trabecular meshwork stem cells

Growing community of inventors

Pittsburgh, PA, United States of America

Joel Steven Schuman